Related Experiment Video
Updated: Jul 11, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Prostate-specific antigen velocity in untreated, localized prostate cancer
Ramachandran Venkitaraman1, Andrew Norman, Ruth Woode-Amissah
1Academic Unit of Radiotherapy & Oncology, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK.
BJU International
|September 14, 2007
Summary
Prostate-specific antigen (PSA) density predicts PSA velocity in men with untreated prostate cancer. This finding may help guide decisions between active surveillance and immediate treatment.
Area of Science:
- Urology
- Oncology
- Prostate Cancer Research
Background:
- Active surveillance is a management strategy for localized prostate cancer.
- Monitoring prostate-specific antigen (PSA) velocity is crucial for treatment decisions.
- Predicting PSA velocity aids in selecting appropriate patients for active surveillance.
Purpose of the Study:
- To identify baseline predictors of PSA velocity in patients with untreated prostate cancer.
- To evaluate the role of PSA density in determining PSA velocity.
Main Methods:
- Prospective study of 237 patients with localized prostate cancer on active surveillance.
- Analysis of baseline clinical characteristics, including PSA density and PSA velocity.
- Multivariate analysis to determine significant predictors of PSA velocity.
Main Results:
- Median follow-up was 24 months.
- PSA density was the sole significant determinant of PSA velocity (P < 0.001).
- Patients with higher PSA density exhibited significantly greater PSA velocity.
Conclusions:
- PSA density is an independent predictor of PSA velocity in localized prostate cancer.
- PSA density can be readily assessed at diagnosis.
- This finding may assist in choosing between active surveillance and radical treatment.
